<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562235</url>
  </required_header>
  <id_info>
    <org_study_id>15681</org_study_id>
    <secondary_id>2014-003952-29</secondary_id>
    <nct_id>NCT02562235</nct_id>
  </id_info>
  <brief_title>Riociguat in Children With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>PATENT-CHILD</acronym>
  <official_title>Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacodynamics and
      pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg,
      1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary
      arterial hypertension (PAH) group 1. The study consists of two phases: titration phase up to
      8 weeks and a maintenance phase up to 16 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 29, 2015</start_date>
  <completion_date type="Anticipated">November 25, 2031</completion_date>
  <primary_completion_date type="Actual">March 7, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in incidence of treatment-emergent adverse events</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in incidence of treatment-emergent serious adverse events</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bone age x-ray of left hand</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of riociguat</measure>
    <time_frame>Day 0, Day 1 (0.5, 1.5 and 2.5h), Day 28, Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-Minute Walking Distance (6MWD)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO functional class</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP or BNP (N-terminal pro-brain natriuretic peptide)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in echocardiograph from baseline</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life scores as assessed by patient questionnaire and PedsQL generic score</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Parent questionnaire and in children able to understand questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire to assess both taste and texture of pediatric formulation(s)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Riociguat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Body-weight adjusted dose equivalent to the exposure of (0.5mg) 1.0 - 2.5 mg three times a day (TID), individual dose titration (IDT) in adults treated for PAH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521)</intervention_name>
    <description>The individual optimal (maintenance) dose is to be determined based on patients' monitoring of systolic blood pressure, well-being and clinical status.</description>
    <arm_group_label>Riociguat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged ≥6 to &lt;18 years

          -  Diagnosed with PAH :

               -  Idiopathic (IPAH)

               -  Hereditable (HPAH)

               -  PAH associated with (APAH)

                    -  Connective tissue disease

                    -  Congenital heart disease with shunt closure more than 6 months ago (no open
                       shunts, confirmed by RHC no less than 4 months after surgery)

        Regardless of the type of PAH, the following findings are not exclusionary:

          -  Patent foramen ovale (PFO) ≤ 1 cm (confirmed by echocardiogram) is not exclusionary

          -  Asymptomatic, isolated, ostium secundum atrial septal defect (OS-ASD) ≤ 1 cm
             (confirmed by echocardiogram) and not associated with hemodynamic alterations
             indicative of significant shunt, e.g. Qp/Qs ratio less &lt;1.5:1 is not exclusionary

               -  Diagnosis of PAH confirmed by right heart catheterization (RHC) at any time prior
                  to enrolment (for patients with closed shunts - RHC no less than 4 months after
                  surgery)

               -  Pulmonary arterial hypertension confirmed by a RHC at any time prior to start of
                  study, with mean pulmonary artery pressure (PAPmean) ≥25 mmHg at rest, pulmonary
                  capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure
                  (LVEDP) ≤15 mmHg, and pulmonary vascular resistance (PVR) &gt;240 dyn•sec•cm-5
                  (i.e., ≥3.0 wood units•m2)

               -  Patients must be on standard of care PAH medications, allowing Endothelin
                  Receptor Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12
                  weeks prior to baseline visit.

               -  Two groups of patients will be included:

          -  Prevalent: Patients currently on monotherapy who need additional treatment (discretion
             of the investigator)

          -  Incident: Treatment naïve patients initiated on PAH medication (allowing ERA and /or
             PCA) and then riociguat added once patients are stable on standard of care

               -  WHO functional class I-III

               -  Adolescent females of childbearing potential can only be included in the study if
                  a pregnancy test is negative. Adolescent females of childbearing potential must
                  agree to use effective contraception and receive sexual counseling as applicable.
                  'Effective contraception' is defined as progestogen-only hormonal contraception
                  associated with inhibition of ovulation (implant), intrauterine device (IUD),
                  intrauterine hormone-releasing system (IUS), or any combination of adequate
                  methods of birth control (e.g. condoms with hormonal contraception). Agreement to
                  use contraception is required from the signing of the informed consent form up
                  until 4 weeks after the last study drug administration.

               -  Young men must agree to use adequate contraception when sexually active.

               -  Written inform consent provided and if applicable child assent provided

        Exclusion Criteria:

          -  Concomitant use of the following medications: phosphodiesterase (PDE) 5 inhibitors
             (such as sildenafil, tadalafil, vardenafil) and non-specific phosphodiesterase (PDE)
             inhibitors (theophylline, dipyridamole), nitrates or NO donors (such as amyl nitrite)
             in any form

          -  Pretreatment with NO donors (e.g. nitrates) within the last 2-weeks before visit 1

          -  Active state of hemoptysis or pulmonary hemorrhage, including those events managed by
             bronchial artery embolization or any history of bronchial artery embolization or
             massive hemoptysis within 3 months prior to screening

          -  Systolic blood pressure (SBP) more than 5 mmHg lower than the age-, sex- and
             height-adapted level of the 50th SBP percentile (NHBPEP, 2004)

          -  History of left-sided heart disease, including valvular disease or heart failure

          -  Pulmonary hypertension related to conditions other than specified in the inclusion
             criteria

          -  Pulmonary veno-occlusive disease

          -  Screening aspartate transaminase (AST) and/ or alanine transaminase (ALT) more than 3
             times the upper limit of normal (ULN)

          -  Severe restrictive lung disease

          -  Severe congenital abnormalities of the lung, thorax, and diaphragm

          -  Clinically relevant hepatic dysfunction (especially Child Pugh C)

          -  Renal insufficiency (estimated glomerular filtration rate &lt;30 mL/min/1.73m2 e.g.
             calculated based on Schwartz formula, for detailed calculation instructions

          -  PH associated with idiopathic interstitial pneumonia (PH-IIP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IPS Centro Médico Imbanaco de Cali S.A.</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy National Cardiology Institute</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale - Università Padova (AOUP)</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center</name>
      <address>
        <city>Obu</city>
        <state>Aichi</state>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>564-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Operadora de Hospitales Angeles S. A. de C. V.</name>
      <address>
        <city>Huixquilucan</city>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiología &quot;Ignacio Chávez&quot;</name>
      <address>
        <city>Mexico D.F.</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital</name>
      <address>
        <city>Kaoshiung</city>
        <zip>81346</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riociguat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

